Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders

INTRODUCTION: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Shih-Hsin, Liu, H. Eugene, Lee, Hsin-Lun, Lin, Chii-Lan, Chen, Wei-Yu, Wu, Zhung-Han, Lin, Sey-En, Chiang, Ling-Ling, Chung, Chi-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871587/
https://www.ncbi.nlm.nih.gov/pubmed/24376677
http://dx.doi.org/10.1371/journal.pone.0083266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871587/
https://www.ncbi.nlm.nih.gov/pubmed/24376677
http://dx.doi.org/10.1371/journal.pone.0083266

Ejemplares similares